GET DAILY SIGNALSPulmatrix (PULM) Q3 2026 Earnings Preview: Merger with Eos SENOLYTIX Takes Center Stage
Key Takeaways
- Pulmatrix (PULM) is expected to report its third-quarter 2026 results in early November, with revenue likely to remain at zero as clinical development stays on hold.
- The central focus is the company's proposed merger with Eos SENOLYTIX, announced at the end of the first quarter of 2026, rather than operating results.
- In the second quarter of 2026, Pulmatrix narrowed its net loss to $1.04 million from $1.55 million a year earlier, reflecting continued cost discipline.
- Cash and cash equivalents stood at $2.2 million as of June 30, 2026, with an additional $0.7 million in restricted cash tied to the merger.
- Analyst coverage remains sparse, so investors will likely focus on cash runway, operating-expense burn, and merger milestones rather than headline figures.
- For more context on the stock, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- Discover automated trading ideas with Trending AI Robots to help streamline your market research.
The Shift from Clinical Development to Corporate Transaction
Pulmatrix has moved from a clinical-stage biopharmaceutical developer to a company focused on completing a corporate transaction. Its patented iSPERSE dry-powder inhalation platform once supported a pipeline targeting respiratory and migraine conditions, but development of lead assets has been paused as management advances the merger with Eos SENOLYTIX. Revenue has therefore been zero for several consecutive quarters. The upcoming earnings release matters less for growth metrics and more for liquidity, spending discipline, and progress on strategic alternatives. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. For investors, the report serves as a checkpoint on whether the company can preserve cash until merger closing and potentially unlock value through asset monetization.
Third-Quarter Expectations
Pulmatrix has not provided formal guidance on specific third-quarter revenue or earnings, and sell-side coverage is limited. Revenue is expected to stay at zero, consistent with the prior two quarters, as clinical development remains on hold and the PUR1900 trial wind-down is complete. The most recent reference point is the second quarter of 2026, when the company reported a net loss of $1.04 million, or $0.29 per share, compared with a net loss of $1.55 million, or $0.42 per share, in the year-ago period. Wall Street’s consensus at the time pointed to roughly a $2.00 loss per share, so the actual result came in meaningfully narrower, driven by steep reductions in research and development and general and administrative spending.
Investors will likely monitor whether the operating-expense base continues to compress, whether the roughly $2.2 million cash balance proves sufficient to reach merger closing, and whether management offers any update on restricted cash or regulatory approvals needed to complete the transaction. As a micro-cap stock with limited float, historical price reactions around earnings have been volatile and tied more to strategic headlines than to the reported loss itself.
Market Sentiment Ahead of the Report
Heading into the third-quarter release, sentiment around Pulmatrix is shaped primarily by the merger process rather than day-to-day fundamentals. The stock trades with a market capitalization around $5 million, and its share price has shown high volatility tied to strategic announcements. Investors appear focused on whether the Eos SENOLYTIX transaction can close, whether cash can be preserved until that point, and whether any clinical assets can be monetized. Key risks include possible merger delays or termination, ongoing cash burn, and limited visibility into future revenue. The market may therefore react more to any merger-related commentary than to the loss per share.
Forward Outlook and Items to Watch
The status of the proposed merger with Eos SENOLYTIX remains the dominant factor. Updates on regulatory approvals, closing conditions, or timing will likely move the stock more than the quarterly numbers. Pulmatrix ended the second quarter with $2.2 million in cash and cash equivalents plus $0.7 million in restricted cash, and management has indicated that current spending levels should support operations at least through the anticipated closing.
Investors should also track progress on monetizing legacy assets. The inhaled antifungal candidate PUR1900 is being developed outside the United States by partner Cipla, which completed a Phase 2 study in India, reported positive results, and received approval from India’s Central Drug Standard Control Organization to begin a Phase 3 trial expected in 2026. Under the arrangement, Pulmatrix would receive 2% royalties on potential future net sales outside the United States.
Cost control continues to matter. General and administrative expenses declined roughly $0.5 million year over year in the second quarter, while research and development spending remained below $0.1 million. Maintaining that discipline will help extend the cash runway. Given the company’s small size and thin liquidity, trading volatility may persist around merger milestones and earnings dates.
Using AI Tools in My Research Process
When evaluating micro-cap situations like this one, I often turn to Tickeron’s AI Screener to quickly filter comparable biotech names by market cap, volatility, and recent performance patterns. It helps surface ideas and benchmark data without manual digging, which is especially useful when coverage is thin and the story centers on a corporate transaction rather than product revenue.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PULM's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for PULM turned positive on October 21, 2026. Looking at past instances where PULM's MACD turned positive, the stock continued to rise in 41 of 48 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 68 cases where PULM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on October 23, 2026. You may want to consider a long position or call options on PULM as a result. In 71 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
PULM moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where PULM advanced for three days, in 166 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
Bearish Trend Analysis
The 10-day RSI Indicator for PULM moved out of overbought territory on September 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 21 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The 10-day moving average for PULM crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PULM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for PULM entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. PULM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.443) is normal, around the industry mean (3.151). P/E Ratio (-1.364) is within average values for comparable stocks, (-1.051). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (127.720) among similar stocks. PULM's P/S Ratio (2500.000) is slightly higher than the industry average of (439.237).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PULM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceuticals for pulmonary disease
Industry Biotechnology
Advertisement